Can gene therapy overcome the problem of hypoxia in radiotherapy?

Journal of Radiation Research

Volumn 41, Issue 3, 2000, Pages 201-212

  Greco, Olga ^a   Patterson, Adam V ^b   Dachs, Gabi U ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bioreductive drugs; GDEPT; Gene delivery; HRE; Radioresistance

Indexed keywords

CONTROLLED DRUG DELIVERY; GENE EXPRESSION; GENE TRANSFER; OXYGEN; RADIOTHERAPY; TARGETED DRUG DELIVERY; TUMORS;

BIOREDUCTIVE DRUGS; GDEPT; GENE DELIVERY; GENES EXPRESSION; HRE; OXYGEN TENSION; PROGNOSTIC MARKERS; RADIORESISTANCE; SOLID TUMORS; TREATMENT OUTCOMES;

GENE THERAPY;

CELL HYPOXIA; GENE THERAPY; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW;

CELL HYPOXIA; GENE THERAPY; HUMANS; NEOPLASMS;

EID: 0034280625     PISSN: 04493060     EISSN: None     Source Type: Journal    
DOI: 10.1269/jrr.41.201     Document Type: Article

References (53)

1. Brown, J. M. and Giaccia, A. J. (1998) The unique physiology of solid tumours: opportunities (and problems) for cancer therapy. Cancer Res. 58: 1408-1416.
2. Vaupel, P. and Höckel, M. (1998) Oxygenation of human tumours. In: Blood perfusion and microenvironment of human tumours. Eds. M. Molls and P. Vaupel, pp. 63-72, Springer-Verlag, Berlin.
3. Brizel, D. M., Sibley. G. S., Prosnitz, L. R., Scher, R. L. and Dewhirst, M. W. (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38: 285-289.
4. Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballengeer, C. A., Weissler, M. C., Fowler, W. C. Jr., Novotny, D. B. and Varia, M. A. (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58: 3765-3768.
5. Nordsmark, M., Keller, J., Hoyer, M., Nielson, O. S., Jensen, O. M. and Overgaard, J. (1998) Hypoxia in human soft tissue sarcomas is associated with poor survival. Raditother. Oncol. 48 (Suppl 1): S162.
6. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Raditother. Oncol. 53: 99-104.
7. Fyles, A. W., Milosevic, M., Wong, R., Kavanagh, M. C., Pintilie, M., Sun, A., Chapman, W., Levin, W., Manchul, L., Keane, T. J. and Hill, R. P. (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Raditother. Oncol. 48: 149-156.
8. Brizel, D. M., Dodge, R. K., Clough, R. W. and Dewhirst, M. W. (1999) Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Raditother. Oncol. 53: 113-117.
9. Höckel, M., Schlenger, K., Höckel, S. and Vaupel, P. (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59: 4525-4528.
10. Alarcon, R. M., Rupnow, B. A., Graeber, T. G., Knox, S. J. and Giaccia, A. J. (1996) Modulation of c-myc activity and apoptosis in vivo. Cancer Res. 56: 4315-4319.
11. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E. Koch, C. J., Lowe, S. W. and Giaccia, A. J. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379: 88-91.
12. Sundfør, K., Lyng, H. and Rofstad, E. K. (1998) Tumor hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer. 76: 822-827.
13. Höckel, M., Schlenger, K., Höckel, S. and Vaupel, P. (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59: 4525-4528.
14. Gómez-Navarro, J., Curiel, D. T. and Douglas, J. T. (1999) Gene therapy for cancer. Eur. J. Cancer. 35: 867-885.
15. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D. and Kim, D. H. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3: 639-645.
16. Durand, R. E. and Raleigh, J. A. (1998) Identification of non-proliferating but viable hypoxic tumour cells in vivo. Cancer Res. 58: 3547-3550.
17. Dachs, G. U., Coralli, C., Hart, S. L. and Tozer G. M. Gene delivery to hypoxic cells in vitro. (2000) Br. J. Cancer. 83: 662-667.
18. Lemmon, M. J., van Zijl, P., Fox, M. E., Mauchline, M. L., Giaccia, A. J., Minton, N. P. and Brown, J. M. (1997) Anaerobic bacteria as a gene delivery system that is controlled by the tumour microenvironment. Gene Therapy. 4:791-796.
19. Lambin, P., Theys, J., Landuyt, W., Rijken, P., van der Kogel, A., van der Schueren, E., Hodgkiss, R., Fowler, J., Nuyts, S., de Bruijn, E., Van Mellaert, L. and Anné, J. (1998) Colonisation of Clostridiuin in the body is restricted to hypoxic cells and necrotic areas of tumours. Anaerobe. 4: 183-188.
20. Pawelek, J. M., Low, K. B. and Bermudes, D. (1997) Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57: 4537-4544.
21. Griffiths, L., Binley, K., Iqball, S., Kan, O., Maxwell, P., Ratcliffe, P., Lewis, C., Harris, A., Kingsman, S. and Naylor, S. (2000) The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Therapy. 7: 255-262.
22. Leek, R. D., Lewis, C. E., Whitehouse, R., Greenall, M., Clarke, J. and Harris, A. L. (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56: 4625-4629.
23. Dachs, G. U. and Chaplin, D. J. (1998) Microenvironmental control of gene expression: implications for tumour angiogenesis, progression, and metastasis. Semin. Radiat. Oncol. 8: 208-216.
24. Blancher, C. and Harris, A. (1998) The molecular basis of the hypoxia responsive pathway: Tumour hypoxia as a therapy target. Cancer Met. Rev. 17: 187-194.
25. O'Rourke, J. F., Dachs, G. U., Gleadle, J. M., Maxwell, P. H., Pugh, C. W., Stratford, I. J., Wood, S.M. and Ratcliffe, P. J. (1997) Hypoxia response elements. Oncol. Res. 9: 327-332.
26. Wenger, R. and Gassman, M. (1997) Oxygen(es) and the hypoxia inducible factor 1. Biol. Chem. 378: 609-616.
27. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza G. L. and Simons, J. W. (1999) Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res. 59: 5830-5835.
28. Dachs, G. U., Patterson, A. V., Firth, J. D, Ratcliffe, P. J., Townsend, K. M. S., Stratford, I. J. and Harris, A. L. (1997) Targeting gene expression to hypoxic tumour cells. Nature Med. 3:515-520.
29. Rinsch, C., Régulier, E., Déglon, N., Dalle, B., Beuzard, Y. and Aebischer, P. (1997) A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum. Gene Ther. 8: 1881-1889.
30. Boast, K., Binley, K., Iqball, S., Price, T., Spearman, H., Kingsman, S., Kingsman, A. and Naylor, S. (1999) Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum. Gene Ther. 10: 2197-2208.
31. Binley K., Iqball, S., Kingsman, S. and Naylor, S. (1999) An adenoviral vector regulated by hypoxia for the treatment of ischemic disease and cancer. Gene Therapy. 6: 1721-1727.
32. Shibata, T., Akiyama, N., Noda, M., Sasai, K. and Hiraoka, M. (1998) Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int. J. Radiat. Oncol. Biol. Phys. 42: 913-916.
33. Shibata, T., Giaccia, A. J. and Brown, J. M. (2000) Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Therapy. 7: 493-498.
34. Dibbens, J. A., Miller, D. L., Damert, A., Risau, W., Vadas, M. A. and Goodall, G. J. (1999) Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol. Biol. Cell. 10: 907-919.
35. Dachs, G. U., Dougherty, G. J., Stratford, I. J. and Chaplin, D. J. (1997) Targeting gene therapy to cancer: a review. Oncol. Res. 9: 313-325.
36. Touraine, R. L., Ishii-Morita, H., Ramsey, W. J. and Blease, R. M. (1998) The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Therapy. 5: 1705-1711.
37. Denning, C. and Pitts, J. D. (1997) Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum. Gene Ther. 8: 1825-1835.
38. Frank, D. K., Frederick, M. J., Liu, T. J. and Clayman, G. L. (1998) Bystander effect of the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin. Cancer Res. 4: 2521-2528.
39. Freeman, S. M., Ramesh, R. and Marrogi, A. J. (1997) Immune system in suicide gene therapy. Lancet. 349: 2-3.
40. Vile, R. G., Castleden, S., Marshall, J., Camplejohn, R., Upton, C. and Chong, H. (1997) Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer. 2: 267-274.
41. Bridgewater, J. A., Knox, R. J., Pitts, J. D., Collins, M. K. and Springer, C. J. (1997) The bystander effect of the nitroreductase CB 1954 enzyme prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 8: 709-717.
42. McNeish, I. A., Searl, P. F., Young, L. S. and Kerr, D. J. (1997) Gene directed enzyme prodrug therapy for cancer. Adv. Drug Deliv. Rev. 26: 173-184.
43. Greco, O., Dachs, G. U., Wardman, P., Folkes, L. K. and Chaplin, D. J. (1999) Development of an enzyme/ prodrug combination for gene therapy of cancer. Proc. Am. Assoc. Cancer Res 40: 478.
44. Greco, O., Tozer, G. M. and Dachs, G. U. (2000) Utilising horseradish peroxidase for hypoxia-induced gene therapy of cancer. Proc. Am. Assoc. Cancer Res. 41: 733.
45. Patterson, A. and Harris, A. L. (1999) Molecular chemotherapy for breast cancer. Drugs Aging. 14: 75-90.
46. Rauth, A. M., Melo, T. and Misra, V. (1998) Bioreductive therapies: an overview of dugs and their mechanism of action. Int. J. Radiat. Oncol. Biol. Phys. 42: 755-762.
47. Haffty, B. G., Son, Y. H., Papac, R., Sasaki, C. T., Weissberg, J. B., Fischer, D., Rockwell, S., Sartorelli, A. C. and Fischer, J. J. (1997) Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J. Clin. Oncol. 15: 268-276.
48. Del Rowe, J., Scott, C., Werner Wasik, M., Bahary, J. P., Curran, W. J., Urtasun, R. C. and Fisher, B. (2000) Single-arm, open-label phase II study of intravenously administered tirapa/amine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 6: 1254-1259.
49. Green, N. K., Youngs, D. J., Neoptolemos, J. P., Fridlos, F., Knox, R. J., Springer, C. J., Anlezpark, G. M., Michael, N. P., Melton, R. G., Ford, M. J., Young, L. S., Kerr, D. J. and Searle, P. F. (1997) Sensitization of colorectal and pancreatic cell lines to the prodrug 5-(aziridin-1-y1)-2.4-dinitrobenzamidine (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 4: 229-238.
50. Drabek, D., Gay, J., Craig, R. and Grosveld, F. (1997) The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB 1954. Gene Therapy. 4: 93-100.
51. Patterson, A. V., Saunders, M. P., Chinje, E. C., Talbot, D. C., Harris, A. L. and Stratford, I. J. (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer. 76: 1338-1347.
52. Patterson, A. V. and Stratford, I. J. (1999) Redox-dependent GDEPT: Combining hypoxia-responsive transcriptional control with oxygen-sensitive prodrug metabolism. Clin. Cancer Res. 5: SS505.
53. Patterson, A. V., Robinson, S. K. and Stratford, I. J. (2000) Evaluation of hypoxia-selective gene therapy in vitro and in vivo: exploiting solid tumor physiology to co-localize "suicide" flavoenzyme expression and prodrug activation. Proc. Am. Assoc. Cancer Res. 41: 733.